The U.S. Food and Drug Administration (FDA) has approved the first generic version of Flovent HFA (fluticasone propionate) inhalation aerosol, marking a major milestone for millions of Americans living with asthma. The generic medicine delivers 44 micrograms per actuation and is authorized for maintenance treatment of asthma in patients aged four years and older. The announcement was posted on the FDA website.
Flovent HFA, an inhaled corticosteroid, helps reduce airway inflammation and prevent symptoms such as wheezing and shortness of breath. The introduction of a generic version is expected to improve affordability and access for families managing this chronic condition, the FDA noted.
“Today’s approval of the first generic fluticasone propionate inhalation aerosol represents an important step in expanding access to affordable asthma treatment,” said Iilun Murphy, MD, director of the FDA’s Office of Generic Drugs. Dr. Murphy emphasized the agency’s commitment to making more safe, effective and lower‑cost medications available to the public.
According to the FDA, asthma affects nearly 25 million Americans, including 4.6 million children, contributing to approximately 10 million asthma attacks and 3,500 deaths annually. FDA officials highlighted that adding a generic maintenance inhaler provides clinicians with an additional — and more accessible — therapy option.
Preventive medications such as Flovent are critical and have been associated with reduced hospitalizations and ICU admissions, said Tracy Beth Høeg, MD, PhD, who is acting director of the Center for Drug Evaluation and Research (CDER) — a division of the FDA.
“With the approval of the first generic metered‑dose inhaler form of the medication, we anticipate increased availability and reduced costs of treating this prevalent, and at times very serious, condition,” Dr. Høeg said.
The generic fluticasone product carries the same warnings, contraindications and precautions as Flovent HFA. The FDA stated it is not intended for treating acute asthma episodes or status asthmaticus. Potential risks include oropharyngeal candidiasis, immunosuppression and hypersensitivity reactions. The agency advised clinicians to review full prescribing information to ensure appropriate use.
The FDA granted its approval to Glenmark Specialty SA, which will manufacture and distribute the generic inhaler. It encouraged patients and clinicians to contact the company for details on product availability. Flovent HFA remains a registered trademark of GlaxoSmithKline.
The FDA granted its approval to Glenmark Specialty SA, which will manufacture and distribute the generic inhaler. It encouraged patients and clinicians to contact the company for details on product availability. Flovent HFA remains a registered trademark of GlaxoSmithKline.
